Cationic Lipid Nanoparticles for Serum-Resistant Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing lipid-based delivery systems are inhibited by serum components, limiting their effectiveness in both in vitro and in vivo applications, and there is a need for improved transfection levels and serum-resistance to enhance therapeutic efficacy and reduce toxicity.
Innovation Solution
Development of novel lipids, such as those represented by Formula (I), which form lipid aggregates, carriers, and nanoparticles that can deliver nucleic acids to cells with high efficiency, serum-resistance, and low toxicity, without the need for additional helper lipids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional lipid-based delivery systems are used, then nucleic acid delivery is achieved under low-serum or serum-free conditions, but serum components inhibit the activity of the lipids, limiting their use in the presence of serum
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by introducing specific molecular features (such as modified head groups, acyl chain compositions, or stereochemical configurations) to change their physical and chemical parameters. These parameter changes enable the lipids to maintain transfection activity in the presence of serum components, thereby resolving the contradiction between transfection efficiency and serum-resistance
Solution Approach 2:
The invention develops composite lipid structures that combine cationic lipid moieties with other functional groups or molecular components. These composite materials exhibit both high transfection efficiency and resistance to serum inhibition, as the combined structure provides synergistic properties that overcome the limitations of conventional single-component lipid systems
2Reliability
If higher levels of transfection are achieved, then therapeutic effect is enhanced, but larger amounts of material may increase potential toxicities
Solution Approach 1:
By optimizing the charge density, hydrophobicity, and molecular size parameters of the cationic lipids, the patent achieves high transfection efficiency at lower material concentrations. These parameter optimizations reduce the total amount of lipid material required, thereby minimizing potential toxicities while maintaining effective gene delivery
Solution Approach 2:
The patent develops lipid formulations that achieve effective transfection with smaller doses, reducing the burden of material accumulation and associated toxicities. The improved efficiency allows for transient, effective delivery without requiring sustained high concentrations that would increase harmful effects
Data Source
AI summary
The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.